Advertisement

Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments

  • Cihat UzunköprüEmail author
  • Yeşim Beckmann
Research
  • 12 Downloads

Abstract

Background

Flammer syndrome (FS) occurs from well-described signs and symptoms. The syndrome itself is not a disease, but it may be a directive marker for advancing therapeutic approaches by predictive and preventive measures as well as for personalization of treatments. The syndrome is related to many diseases, but FS has been rarely studied in multiple sclerosis (MS). The study aimed to determine whether FS signs and symptoms occur more often in people with MS than in healthy controls, and in order to personalize the treatment, we investigated the possible effect of current therapies on FS signs and symptoms.

Methods

Two hundred twenty-two MS patients and 203 healthy controls answered the questionnaire consisting of 15 signs and symptoms of FS.

Results

MS patients had significantly more complaints in 9 items of FS signs and symptoms (cold hands or/and feet, the reduced feeling of thirst, dizziness, drug side effects, other headaches (tension-type, medication overuse), weight loss, feeling cold, long sleep-onset time, and skin blotches) compared to healthy controls. Six items (low blood pressure, tinnitus, increased odor sensitivity, low pain threshold, and perfectionism) were similar between the two groups. The treatment agents currently used did not have any effect on the signs and symptoms of FS.

Conclusion

This study showed that FS might be associated with MS. Injectable or oral agents are not related to the signs and symptoms of FS. Further studies are needed to validate this association.

Relevance of the article for predictive, preventive, and personalized medicine

FS is common among MS patients. Being aware of this incidence that might impair the life quality of MS patients is useful to predict the comorbidity and develop preventive strategies and applying personalized treatment options and procedures.

Keywords

Multiple sclerosis Primary vascular dysregulation Flammer syndrome 

Notes

Compliance with ethical standards

All the patient investigations conformed to the principles outlined in the Declaration of Helsinki and have been performed with the permission of the Ethics Committee of İzmir Katip Çelebi University. The study was approved by the Ethics Committee of İzmir Katip Çelebi University. All the patients were informed about the purposes of the study and have signed their “consent of the patient.” This article does not contain any studies with animals performed by any of the authors.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Dobson R, Giovanni G. Multiple sclerosis: a review. Eur J Neurol. 2018;26:27–40.  https://doi.org/10.1111/ene.13819.CrossRefGoogle Scholar
  2. 2.
    Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3:e279.  https://doi.org/10.1212/NXI.0000000000000279.CrossRefGoogle Scholar
  3. 3.
    Pawlitzki M, Neumann J, Kaufmann J, Heidel j SE, Sweeney-Reed C, Sailer M, et al. Loss of corticospinal tract integrity in early MS disease stages. Neurol Neuroimmunol Neuroinflamm. 2017;4:e399.  https://doi.org/10.1212/NXI.0000000000000399.CrossRefGoogle Scholar
  4. 4.
    Hemond CC, Healy BC, Tauhid S, Mazzola MA, Quintana FJ, Gandhi R, et al. MRI phenotypes in MS: longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019;6:e530.  https://doi.org/10.1212/NXI.0000000000000530.CrossRefGoogle Scholar
  5. 5.
    Spanò B, Giulietti G, Pisani V, Morreale M, Tuzzi E, Nocentini U, et al. Disruption of neurite morphology parallels MS progression. Neurol Neuroimmunol Neuroinflamm. 2018;5:e502.  https://doi.org/10.1212/NXI.0000000000000502.CrossRefGoogle Scholar
  6. 6.
    Kemenyova P, Siarnik P, Sutovsky S, Blaho A, Turcani P, Kolar B. Impairment of endothelial function in patients with multiple sclerosis. Neuro Endocrinol Lett. 2015;36:67–71.Google Scholar
  7. 7.
    Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multipl Scler. 2015;21:318–21.  https://doi.org/10.1177/1352458514564485.CrossRefGoogle Scholar
  8. 8.
    Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5:11.  https://doi.org/10.1186/1878-5085-5-11.CrossRefGoogle Scholar
  9. 9.
    Bae KH, Go HY, Park KH, Ahn I, Yoon Y, Lee S. The association between cold hypersensitivity in the hands and feet and chronic disease: results of a multicentre study. BMC Complement Altern Med. 2018;18(1):40.  https://doi.org/10.1186/s12906-018-2082-3.CrossRefGoogle Scholar
  10. 10.
    Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring J. Multiple sclerosis and primary vascular dysregulation (Flammer syndrome). EPMA J. 2016;15:7–13.  https://doi.org/10.1186/s13167-016-0062-6.Google Scholar
  11. 11.
    Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J. 2013;4(14).  https://doi.org/10.1186/1878-5085-4-14.
  12. 12.
    Haider L. Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxidative Med Cell Longev. 2015;2015(725370):1–10.  https://doi.org/10.1155/2015/725370.CrossRefGoogle Scholar
  13. 13.
    Flammer J, Konieczka K. The discovery of the Flammer syndrome: a historical and personal perspective. EPMA J. 2017;8:75–92.  https://doi.org/10.1007/s13167-017-0090-x.CrossRefGoogle Scholar
  14. 14.
    Lucas RM, Rodney Harris RM. On the nature of evidence and ‘proving’ causality: smoking and lung cancer vs. sun exposure, vitamin D and multiple sclerosis. Int J Environ Res Public Health. 2018;12, 15(8).  https://doi.org/10.3390/ijerph15081726.
  15. 15.
    Rocha NP, Colpo GD, Bravo-Alegria J, Lincoln JA, Wolinsky JS, Lindsey JW, et al. Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis. J Neuroimmunol. 2018;326:45–8.  https://doi.org/10.1016/j.jneuroim.2018.11.007.CrossRefGoogle Scholar
  16. 16.
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.  https://doi.org/10.1002/ana.22366.CrossRefGoogle Scholar
  17. 17.
    Konieczka K, Choi HJ, Koch S, Fankhauser F, Schoetzau A, Kim DM. Relationship between normal tension glaucoma and Flammer syndrome. EPMA J. 2017;8:111–7.  https://doi.org/10.1007/s13167-017-0097-3.CrossRefGoogle Scholar
  18. 18.
    Barin L, Salmen A, Disanto G, Babačić H, Calabrese P, Chan A, et al. The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? Multipl Scler Relat Disord. 2018;25:112–21.  https://doi.org/10.1016/j.msard.2018.07.013.CrossRefGoogle Scholar
  19. 19.
    Filingeri D, Chaseling G, Hoang P, Barnett M, Davis SL, Jay O. Afferent thermosensory function in relapsing-remitting multiple sclerosis following exercise-induced increases in body temperature. Exper Physiol. 2017;107:887–93.  https://doi.org/10.1113/EP086320.CrossRefGoogle Scholar
  20. 20.
    Davis SL, Jay O, Wilson TE. Thermoregulatory dysfunction in multiple sclerosis. Handb Clin Neurol. 2018;157:701–14.  https://doi.org/10.1016/B978-0-444-64074-1.00042-2.CrossRefGoogle Scholar
  21. 21.
    Keller DM, Fadel PJ, Hamsberger MA, Remington GM, Frohman EM, Davis SL. Reduced spontaneous sympathetic nerve activity in multiple sclerosis patients. J Neurol Sci. 2014;344:210–4.  https://doi.org/10.1016/j.jns.2014.06.053.CrossRefGoogle Scholar
  22. 22.
    Speciale L, Sarasella M, Ruzzante S, Caputo D, Mancuso R, Calvo MG. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neuro-Oncol. 2006;2:62–6.Google Scholar
  23. 23.
    Haufschild T, Shaw SG, Kesselring J, Flammer J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol. 2001;21:37–8.CrossRefGoogle Scholar
  24. 24.
    Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65:883–91.  https://doi.org/10.1136/jim-2016-000339.CrossRefGoogle Scholar
  25. 25.
    Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017;16:1359–71.  https://doi.org/10.1080/14740338.2017.1388371.CrossRefGoogle Scholar
  26. 26.
    Putzki N, Katsarava Z. Headache in multiple sclerosis. Curr Pain Headache Rep. 2010;14:316–20.  https://doi.org/10.1007/s11916-010-0126-6.CrossRefGoogle Scholar
  27. 27.
    Kister I, Caminero AB, Herbert J, Lipton RB. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14:441–8.  https://doi.org/10.1007/s11916-010-0143-5.CrossRefGoogle Scholar
  28. 28.
    Beckmann Y, Türe S. Headache characteristics in multiple sclerosis. Mult Scler Relat Disord. 2018;27:112–6.  https://doi.org/10.1016/j.msard.2018.09.022.CrossRefGoogle Scholar
  29. 29.
    Husain F, Pardo G, Rabadi M. Headache and its management in patients with multiple sclerosis. Curr Treat Options Neurol. 2018;20(4):10.  https://doi.org/10.1007/s11940-018-0495-4.CrossRefGoogle Scholar
  30. 30.
    Gustavsen MW, Celius EG, Winsvold BS, Moen SM, Nygaard GO, Berg-Hansen P, et al. Migraine and frequent tension-type headache are not associated with multiple sclerosis in a Norwegian case-control study. Multipl Scler J Exp Transl Clin. 2016;12(2):20.  https://doi.org/10.1177/2055217316682976.Google Scholar
  31. 31.
    Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;80:548–52.  https://doi.org/10.1212/WNL.0b013e31828154f3.CrossRefGoogle Scholar
  32. 32.
    Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sørensen TIA, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler. 2013;19:1323–9.  https://doi.org/10.1177/1352458513483889.CrossRefGoogle Scholar
  33. 33.
    Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85:240–7.  https://doi.org/10.1212/WNL.0000000000001718.CrossRefGoogle Scholar
  34. 34.
    Marrie RA, Elliot L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology. 2015;84:350–8.  https://doi.org/10.1212/WNL.0000000000001187.CrossRefGoogle Scholar
  35. 35.
    Mowry EM, Azevedo CJ, McCulloch CE, Okuda DT, Lincoln RR, Waubant E, et al. Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology. 2018;91:e2256–64.  https://doi.org/10.1212/WNL.0000000000006644.CrossRefGoogle Scholar
  36. 36.
    Payne C, Wiffen PJ, Martin S. WITHDRAWN: interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Syst Rev. 2017;4:CD008427. https://doi.org/10.1002/14651858.CD008427.pub3.
  37. 37.
    Braley TJ. Overview: a framework for the discussion of sleep in multiple sclerosis. Curr Sleep Med Rep. 2017;3:263–71.CrossRefGoogle Scholar
  38. 38.
    Veauthier C, Hasselmann H, Gold SM, Paul F. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J. 2016;7:25.  https://doi.org/10.1186/s13167-016-0073-3.CrossRefGoogle Scholar
  39. 39.
    Braley TJ, Boudreau EA. Sleep disorders in multiple sclerosis. Curr Neurol Neurosci Rep. 2016;16:50.  https://doi.org/10.1007/s11910-016-0649-2.CrossRefGoogle Scholar
  40. 40.
    Veauthier C, Gaede G, Radbruch H, Wernecke KD, Paul F. Sleep disorders reduce health-related quality of life in multiple sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis). Int J Mol Sci. 2015;16:16514–28.  https://doi.org/10.3390/ijms160716514.CrossRefGoogle Scholar
  41. 41.
    Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15:5–14.  https://doi.org/10.1016/j.sleep.2013.08.791.CrossRefGoogle Scholar
  42. 42.
    Sahraian MA, Rezaali S, Hosseiny M, Doosti R, Tajik A, Naser Moghadasi A. Sleep disorder as a triggering factor for relapse in multiple sclerosis. Eur Neurol. 2017;77:258–61.  https://doi.org/10.1159/000470904.CrossRefGoogle Scholar
  43. 43.
    Amtmann D, Askew RL, Kim J, Chung H, Ehde DM, Bombardier CH, et al. Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis. Rehabil Psychol. 2015;60:81–90.  https://doi.org/10.1037/rep0000027.CrossRefGoogle Scholar
  44. 44.
    Maurelli M, Bergamaschi R, Antonini A, Fargnoli MC, Puma E, Mallucci G, et al. Interferon-beta injection site reactions in patients with multiple sclerosis. J Dermatalog Treat. 2018;29:831–4.  https://doi.org/10.1080/09546634.2018.1467539.CrossRefGoogle Scholar
  45. 45.
    Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–6.  https://doi.org/10.1016/j.msard.2018.05.007.CrossRefGoogle Scholar
  46. 46.
    Golubnitschaja O, Flammer J. Individualised patient profile: clinical utility of Flammer syndrome phenotype and general lessons for predictive, preventive and personalised medicine. EPMA J. 2018;9:15–20.  https://doi.org/10.1007/s13167-018-0127-9.CrossRefGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019

Authors and Affiliations

  1. 1.Department of Neurologyİzmir Katip Çelebi UniversityİzmirTurkey

Personalised recommendations